Jade Biosciences Files S-1 for $45M PIPE Resale; Nasdaq Listing Continues

Ticker: JBIO · Form: S-1 · Filed: Dec 22, 2025 · CIK: 1798749

Sentiment: mixed

Topics: S-1 Filing, Private Placement, Resale Offering, Biopharmaceutical, Autoimmune Diseases, Clinical Stage, Stock Dilution, Capital Markets

Related Tickers: JBIO

TL;DR

**JBIO's S-1 for PIPE resale means potential dilution and selling pressure, so watch the $17.03 price point closely.**

AI Summary

Jade Biosciences, Inc. (JBIO) filed an S-1 registration statement on December 22, 2025, for the resale of up to 3,214,286 shares of common stock by a single selling stockholder. These shares were acquired in a private placement (December 2025 PIPE) on December 16, 2025, at a price of $14.00 per share, generating approximately $45.0 million for the company. JBIO will not receive any proceeds from this specific resale offering. The company previously completed a significant business combination on April 28, 2025, merging Aerovate Therapeutics, Inc. with Pre-Merger Jade, which included a 1-for-35 reverse stock split of Aerovate common stock. In connection with this merger, a Pre-Closing Financing raised an aggregate of $334.2 million through the issuance of 43,947,116 shares of common stock and 12,305,898 pre-funded warrants at $5.9407 per share or $5.9406 per warrant. Additionally, an October 2025 PIPE on October 8, 2025, raised approximately $135 million by selling 13,368,164 shares of common stock at $9.14 per share and pre-funded warrants for 1,402,092 shares at $9.1399 per warrant. As of September 30, 2025, JBIO had 32,626,730 shares of common stock outstanding. The company is a clinical-stage biopharmaceutical firm developing JADE101 for IgA nephropathy and JADE201 for multiple autoimmune disorders.

Why It Matters

This S-1 filing signals a significant liquidity event for the accredited investor who participated in the December 2025 PIPE, allowing them to monetize their investment in Jade Biosciences. For existing investors, the potential influx of 3,214,286 shares into the market could create selling pressure, impacting JBIO's stock price, which closed at $17.03 on December 19, 2025. The company's strategy to fund its clinical-stage biopharmaceutical development, including JADE101 and JADE201, relies on these private placements, making the market's absorption of these shares crucial. Competitively, successful capital raises enable JBIO to advance its pipeline against other biopharmaceutical companies in the autoimmune disease space.

Risk Assessment

Risk Level: medium — The S-1 filing itself is for a resale, meaning the company will not receive proceeds, but the offering of 3,214,286 shares by a single selling stockholder could introduce significant selling pressure on JBIO's stock, which traded at $17.03 on December 19, 2025. As a 'smaller reporting company' and 'emerging growth company,' JBIO faces inherent risks associated with limited operating history and reliance on successful clinical development of JADE101 and JADE201.

Analyst Insight

Investors should monitor the trading activity of JBIO closely following the effective date of this S-1, as the selling stockholder's disposition of 3,214,286 shares could impact market price. Consider the potential for increased supply of shares and its effect on demand, especially given the stock's recent closing price of $17.03.

Financial Highlights

debt To Equity
N/A
revenue
N/A
operating Margin
N/A
total Assets
N/A
total Debt
N/A
net Income
N/A
eps
N/A
gross Margin
N/A
cash Position
N/A
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What is the purpose of Jade Biosciences' S-1 filing on December 22, 2025?

The S-1 filing by Jade Biosciences, Inc. (JBIO) on December 22, 2025, is for the registration of up to 3,214,286 shares of common stock for resale by a specific selling stockholder. These shares were acquired in a private placement on December 16, 2025, for approximately $45.0 million.

Will Jade Biosciences receive any proceeds from the sale of shares in this S-1 offering?

No, Jade Biosciences, Inc. will not receive any proceeds from the sale or other disposition of the 3,214,286 Resale Shares by the Selling Stockholder under this prospectus. The proceeds will go directly to the selling stockholder.

What was the price per share for the December 2025 PIPE for Jade Biosciences?

The Selling Stockholder purchased an aggregate of 3,214,286 shares of Jade Biosciences' Common Stock at a price per share of $14.00 in the December 2025 PIPE, for an aggregate purchase price of approximately $45.0 million.

What is Jade Biosciences' primary business focus?

Jade Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel biologic therapies for patients with autoimmune diseases. Their lead product candidate, JADE101, targets IgA nephropathy, and JADE201 targets multiple autoimmune disorders.

When did Jade Biosciences complete its business combination and what was its impact?

Jade Biosciences consummated its business combination on April 28, 2025, merging Aerovate Therapeutics, Inc. with Pre-Merger Jade. This involved a 1-for-35 reverse stock split of Aerovate common stock and a Pre-Closing Financing that raised an aggregate of $334.2 million.

What was the last reported sale price for Jade Biosciences' common stock?

On December 19, 2025, the last reported sale price for Jade Biosciences' Common Stock (JBIO) on The Nasdaq Capital Market was $17.03 per share.

How many shares of common stock did Jade Biosciences have outstanding as of September 30, 2025?

As of September 30, 2025, there were 32,626,730 shares of Jade Biosciences' Common Stock outstanding.

What are the potential risks for investors related to this S-1 filing for Jade Biosciences?

A key risk for investors is the potential for increased selling pressure on JBIO's stock as the Selling Stockholder disposes of 3,214,286 shares. This could impact the market price, especially given the company's status as a 'smaller reporting company' and 'emerging growth company' with inherent development risks.

What was the total amount raised in the October 2025 private placement for Jade Biosciences?

On October 8, 2025, Jade Biosciences completed the October 2025 PIPE, raising an aggregate purchase price of approximately $135 million through the sale of 13,368,164 shares of Common Stock and pre-funded warrants for 1,402,092 shares.

Who is the CEO of Jade Biosciences, Inc.?

Tom Frohlich is the Chief Executive Officer of Jade Biosciences, Inc. His contact information is listed at 221 Crescent St., Building 23, Suite 105, Waltham, MA 02453, with a telephone number of (781) 312-3013.

Risk Factors

Industry Context

Jade Biosciences operates in the highly competitive and capital-intensive biopharmaceutical sector, focusing on developing treatments for IgA nephropathy and autoimmune disorders. The industry is characterized by long development cycles, significant regulatory hurdles, and the need for substantial funding to advance drug candidates through clinical trials. Success hinges on innovation, effective clinical trial execution, and securing necessary regulatory approvals.

Regulatory Implications

As a clinical-stage biopharmaceutical company, Jade Biosciences is subject to stringent regulatory oversight from bodies like the FDA. The success of its product candidates, JADE101 and JADE201, depends entirely on navigating the complex and lengthy approval process. Any delays or failures in clinical trials or regulatory submissions could severely impact the company's prospects.

What Investors Should Do

  1. Monitor clinical trial progress and regulatory updates for JADE101 and JADE201.
  2. Assess the company's ongoing financing needs and ability to secure future capital.
  3. Evaluate the competitive landscape for IgA nephropathy and autoimmune disorder treatments.
  4. Review the terms and implications of recent financing rounds, including the December 2025 PIPE.

Key Dates

Glossary

S-1 Registration Statement
A form filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. It contains detailed information about the company's business, financial condition, and management. (This filing initiates the process for the resale of shares by a selling stockholder, providing key details about the company and the offering.)
PIPE (Private Investment in Public Equity)
A transaction where a public company sells its securities directly to a private investor, often at a discount to the market price. (Jade Biosciences has completed two PIPE transactions in 2025, raising significant capital through private placements of its common stock and warrants.)
Pre-funded Warrants
A type of warrant that allows the holder to purchase shares of common stock at a nominal exercise price (often $0.0001), effectively representing an immediate purchase of stock rather than a future option. (These were issued in the October and December 2025 PIPE transactions, indicating a structure to facilitate immediate ownership for investors.)
Reverse Stock Split
A corporate action where a company reduces the number of its outstanding shares by consolidating them, typically to increase the per-share price. (Aerovate Therapeutics, Inc. underwent a 1-for-35 reverse stock split prior to its merger with Pre-Merger Jade, impacting the share structure.)
Clinical-Stage Biotechnology Company
A company focused on developing new drugs or therapies that are currently undergoing clinical trials but have not yet received regulatory approval for sale. (This describes Jade Biosciences' current operational status, highlighting its focus on research and development rather than commercial sales.)

Year-Over-Year Comparison

This S-1 filing follows a period of significant corporate activity for Jade Biosciences, including a major business combination and two substantial PIPE financings in 2025. While specific comparative financial metrics like revenue and net income are not yet applicable for a clinical-stage company, the filing highlights a substantial increase in capital raised ($45.0 million in Dec 2025 PIPE, $135 million in Oct 2025 PIPE, and $334.2 million in pre-closing financing) compared to prior periods. New risks related to the ongoing clinical development of JADE101 and JADE201 and the potential for future financing needs are now prominent.

Filing Stats: 4,503 words · 18 min read · ~15 pages · Grade level 15.6 · Accepted 2025-12-22 16:38:10

Key Financial Figures

Filing Documents

USE OF PROCEEDS

USE OF PROCEEDS 51

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 52

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 73

BUSINESS

BUSINESS 74 MANAGEMENT 127

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 134 AEROVATE EQUITY COMPENSATION PLAN INFORMATION 142

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 143 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 147 SELLING STOCKHOLDER 154 PLAN OF DISTRIBUTION 155

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 158 LEGAL MATTERS 163 EXPERTS 164 WHERE YOU CAN FIND MORE INFORMATION 165 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 i Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of the registration statement that we filed with the SEC using a "shelf" registration process. Under this shelf registration process, the Selling Stockholder may, from time to time, sell the securities described in this prospectus in one or more offerings. This prospectus contains information that you should consider when making your investment decision. Neither we, nor the Selling Stockholder, have authorized anyone to give any information or to make any representation other than those contained in this prospectus. The Selling Stockholder is offering to sell, and seeking offers to buy, our securities only in jurisdictions where it is lawful to do so. We have not authorized anyone to provide you with different information. This prospectus and any accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other than the securities described in any accompanying prospectus supplement or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information appearing in this prospectus, any prospectus supplement and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed materially since those dates. In this prospectus, unless the context otherwise requires, the terms "Jade," the "Company," "we," "us," and "our" refer to Jade Biosciences, Inc., a Nevada corporation, and its consolidated subsidiaries. This prospectus contains trade names, trademarks and service marks of others, which are the property of their respective owners. Solely for conv

Use of Proceeds

Use of Proceeds We will not receive any proceeds from the sale of the Resale Shares offered by the Selling Stockholder under this prospectus. The net proceeds from the sale of the Resale Shares offered by this prospectus will be received by the Selling Stockholder. See the section titled "Use of Proceeds."

Risk Factors

Risk Factors See the section titled "Risk Factors" and other information included in this prospectus for a discussion of factors that you should consider carefully before deciding to invest in our securities. Stock Market Symbol Our Common Stock is listed on The Nasdaq Capital Market under the symbol "JBIO." The number of issued and outstanding shares of Common Stock does not include the following, as of September 30, 2025 unless otherwise noted: 12,622,000 shares of Common Stock issuable upon the conversion of 12,622 shares of Series A Preferred Stock; 13,368,164 October 2025 PIPE Shares issued subsequent to September 30, 2025 in the October 2025 PIPE; 1,402,092 shares of Common Stock issuable upon the exercise of October 2025 PIPE Pre-Funded Warrants with an exercise price of $0.0001 per share issued subsequent to September 30, 2025 in the October 2025 PIPE; 3,214,286 shares of Common Stock issued subsequent to September 30, 2025 in the December 2025 PIPE; 7,375,394 shares of Common Stock issuable upon the exercise of 7,375,394 pre-funded warrants to acquire shares of Common Stock with an exercise price of $0.0001 per share; 7,449,487 shares of Common Stock issuable upon the exercise of stock options outstanding under the Jade Biosciences, Inc. 2024 Equity Incentive Plan with a weighted-average exercise price of $4.76 per share; 2,251,408 shares of Common Stock issuable upon the exercise of stock options outstanding under the Jade Biosciences, Inc. 2025 Stock Incentive Plan (the "2025 Plan") with a weighted-average exercise price of $9.28 per share; 6,260,494 shares of Common Stock reserved for issuance under our 2025 Plan; and 4 Table of Contents 526,241 shares of Common Stock reserved for issuance under our 2025 Employee Stock Purchase Plan. For additional information concerning the offering, see the section titled " Plan of Distribution ." 5 Table of Contents RISK FACTOR SUMMARY The following summarizes the principal facto

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing